Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel, for the month of January 2020. The filing reports on corporate governance actions taken on January 6, 2020, following an adjourned special general meeting of shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a report of a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the election of Ms. Sivan Rahamim as an external director for a three-year term. Her compensation will be determined in accordance with the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document strictly addresses the outcome of the shareholder vote regarding board composition.
Key Facts for Investor Verification
- Ms. Sivan Rahamim was elected as an external director for a three-year term on January 6, 2020.
- Director compensation is governed by Israeli Companies Regulations 5760-2000.
- The filing incorporates by reference into various Registration Statements on Forms S-8 and F-3.
- No financial data or operational metrics are disclosed in this specific filing.